Skip to content
Research/Peptide Blends Stacks/Ipamorelin + Sermorelin

Ipamorelin + Sermorelin

GH secretagogue blend. Combination of two GH secretagogues with complementary mechanisms. Sermorelin provides GHRH activity, Ipamorelin adds GHRP component.

Intelligence Profile

Clinical Applications

The clinical evidence for Ipamorelin + Sermorelin combination therapy is extremely limited, with no dedicated clinical trials identified for this specific combination. The available literature consists primarily of review articles discussing growth hormone secretagogues in general contexts.

Reported Uses

Based on the limited available evidence, this peptide combination appears to be used primarily for:

Body Composition Management

  • One review from 2020 discusses the role of growth hormone secretagogues in managing body composition in hypogonadal males, though specific efficacy data for the Ipamorelin + Sermorelin combination is not provided.

Athletic Performance and Recovery

  • Multiple 2026 reviews mention peptide therapies being used for musculoskeletal injuries and athletic performance enhancement, though these discussions appear to focus on unapproved or off-label uses rather than evidence-based clinical applications.

Evidence Limitations

The current literature reveals significant gaps in clinical evidence:

  • No controlled clinical trials specifically evaluating the Ipamorelin + Sermorelin combination have been identified
  • Available studies are primarily review articles rather than original research
  • Much of the discussion centers on unapproved or off-label uses in athletic and bodybuilding contexts
  • Safety and efficacy data specific to this combination therapy is lacking

Regulatory Considerations

Several reviews from 2026 characterize peptide therapies in this category as involving "approved and unapproved" treatments, suggesting regulatory uncertainty around clinical use of this combination.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. The limited clinical evidence available makes it difficult to draw definitive conclusions about safety or efficacy. Patients considering peptide therapies should consult with qualified healthcare providers who can evaluate individual circumstances and current regulatory status.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.